Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK."
Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic.
This molecule was developed to selectively stimulate a specific adenosine subreceptor, and was developed initially to prevent apoptosis following ischemia-reperfusion injuries such as stroke or myocardial infarction. In the eye, stimulation of this same receptor has the effect of augmenting the intrinsic function of the eye's trabecular meshwork, or TM, which is the main passageway for transporting the aqueous humor, a liquid that maintains the eye's shape and typically experiences elevated pressure in glaucoma. We believe that by enhancing this naturally occurring TM process, rather than changing the fundamental dynamics of pressure regulation in the eye, trabodenoson's mechanism of action should result in a lower risk of unintended side effects and long term safety or tolerability issues. Additionally, trabodenoson's unique mechanism of action in the TM should complement the activity of existing products that lower IOP by addressing different parts of the in-flow and out-flow system of the eye.
Trabodenoson has completed Phase 2 clinical development in primary open-angle glaucoma (POAG) and ocular hypertensive (OHT) patients and is ready for Phase 3. Trabodenoson, if ultimately approved by regulatory agencies, will be a valuable, innovative product that ophthalmologists can use alone or in combination with other approved medicines for glaucoma, and would also be a new treatment option for those patients who are refractory to current drug therapies.
The neuroprotective potential of trabodenoson is supported by the basic biology of adenosine, which has shown that stimulation of the A1 receptor by endogenous adenosine protects tissues of the central nervous system. A pre-clinical study of the impact of high IOP on retinal ganglion cells showed that trabodenoson could protect this key population of cells in the retina that, when lost, results in the irreversible vision loss. A preclinical program investigating a number of currently untreatable degenerative retinal diseases that would benefit from the neuroprotective action of trabodenoson is ongoing with the goal of supporting proof-of-concept clinical trials.
Inotek, in addition to having built a potential first-in-class ophthalmic product candidate in trabodenoson, has an experienced management team with a track record of multiple successful NDA approvals and successful product launches. Inotek intends to advance its programs through regulatory approval and to market its ophthalmology products, a specialty area, with a relatively small and focused sales and marketing team. The Company is based in Lexington, MA.